Trial Profile
A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects With Advanced Malignancies Previously Enrolled in Other XL184 Studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2013
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 28 Sep 2012 New trial record